ethacrynic acid has been researched along with Ovarian Neoplasms in 6 studies
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pineal hormone melatonin has been reported to have in vitro antiproliferative effects on estrogen receptor-positive human breast cancer cell lines at concentrations near to plasma physiological concentrations (1 x 10(-11) to 1 x 10(-9) M)." | 3.70 | Effects of melatonin on proliferation of cancer cell lines. ( Dimitriadis, KA; Geromichalos, GD; Kortsaris, AH; Kouretas, D; Papazisis, KT; Sivridis, E; Tsekreli, OK, 1998) |
| "When ethacrynic acid was present during the 7-day exposure of the cells to melphalan, the development of drug resistance was prevented." | 1.30 | Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid. ( Caffrey, PB; Chinen, N; Frenkel, GD; Zhang, Y; Zhu, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, B | 1 |
| Tong, T | 1 |
| Wang, X | 1 |
| Liu, F | 1 |
| Zhang, X | 1 |
| Hu, X | 1 |
| Li, X | 1 |
| Yang, X | 1 |
| Liao, F | 1 |
| Păunescu, E | 1 |
| Soudani, M | 1 |
| Clavel, CM | 1 |
| Dyson, PJ | 1 |
| Maeda, O | 1 |
| Terasawa, M | 1 |
| Ishikawa, T | 1 |
| Oguchi, H | 1 |
| Mizuno, K | 1 |
| Kawai, M | 1 |
| Kikkawa, F | 1 |
| Tumoda, Y | 1 |
| Hidaka, H | 1 |
| Papazisis, KT | 1 |
| Kouretas, D | 1 |
| Geromichalos, GD | 1 |
| Sivridis, E | 1 |
| Tsekreli, OK | 1 |
| Dimitriadis, KA | 1 |
| Kortsaris, AH | 1 |
| Caffrey, PB | 1 |
| Zhu, M | 1 |
| Zhang, Y | 1 |
| Chinen, N | 1 |
| Frenkel, GD | 1 |
| Lewis, AD | 1 |
| Durán, GE | 1 |
| Lau, DH | 1 |
| Sikic, BI | 1 |
6 other studies available for ethacrynic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Short divalent ethacrynic amides as pro-inhibitors of glutathione
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Dru | 2022 |
Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates.
Topics: Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; Enzyme Inhibitors; Ethacrynic Acid; Fem | 2017 |
A newly synthesized bifunctional inhibitor, W-77, enhances adriamycin activity against human ovarian carcinoma cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calmodulin; Cell Survival; Cystadenocarcino | 1993 |
Effects of melatonin on proliferation of cancer cell lines.
Topics: Breast Neoplasms; Buthionine Sulfoximine; Cell Division; Cell Survival; Colonic Neoplasms; DNA Repli | 1998 |
Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid.
Topics: Antineoplastic Agents, Alkylating; Blotting, Northern; Drug Resistance, Neoplasm; Ethacrynic Acid; F | 1999 |
Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism.
Topics: Antibiotics, Antineoplastic; Buthionine Sulfoximine; Cell Survival; Doxorubicin; Drug Resistance; Et | 1992 |